Study of SHR-A1811 for triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a new drug called SHR-A1811 for people with triple-negative breast cancer that has spread or come back. It looks at whether the drug can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and female.
- You have triple-negative breast cancer that has come back or spread (and cannot be removed by surgery).
- Your doctor expects you to live at least 12 more weeks.
- Your liver and kidneys are working well enough.
- You have not had active brain tumors that haven't been treated, other cancers recently, or serious heart or lung problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new drug combination called SHR-A1811 can help people with cervical cancer that has come back or spread. It aims to find a better treatment option for those who have limited choices.
This study tests a new drug called SHR-A1811, given by different methods, to find the best way to treat advanced HER2-positive breast cancer. It may help if you have had few treatments so far and have not had this type of drug before.
This study tests a new targeted drug (SHR-A1811) for breast cancer that has very low HER2 levels. The drug is designed to attack cancer cells with this specific marker, and the study aims to see if it can help slow the cancer's growth.
This Phase 2 trial tests a treatment for people with triple-negative breast cancer that has come back or spread and has continued to progress despite earlier therapies. It may help by trying a new approach in patients who still have enough health to safely receive more treatment.
This trial tests a new drug called SHR-A1811 for women with HER2-positive breast cancer that did not shrink enough after the first four rounds of chemotherapy before surgery. The goal is to see if this drug can improve outcomes for patients who need a different treatment approach.
This study tests an experimental drug called SHR-A1811 given as a shot under the skin (subcutaneous injection) for people with solid tumors. It aims to see if the drug is safe and how well it works.
Hear when a new PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.